Tatsis Ourania 4

What Happened

• Ourania Tatsis, EVP & Chief Regulatory & Quality Officer at Vertex Pharmaceuticals (VRTX), disposed of a total of 2,606 shares in two transactions on Feb 10–11, 2026, generating roughly $1,216,957 in proceeds. On 2026-02-10, 2,140 shares were disposed at $468.41 each ($1,002,397) as a payment of exercise price or tax liability (share withholding). On 2026-02-11, 466 shares were sold in the open market at $460.43 each ($214,560). These are sales/withholdings (not purchases) and are typically routine (tax/option related) rather than a demonstrated bullish purchase.

Key Details

• Transaction dates & prices:
  • 2026-02-10: 2,140 shares disposed @ $468.41 = $1,002,397 (code F: payment of exercise price or tax liability / shares withheld)
  • 2026-02-11: 466 shares sold @ $460.43 = $214,560 (open-market sale)
• Combined proceeds: approximately $1,216,957.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: Transactions were made pursuant to Dr. Tatsis’ company-approved Rule 10b5-1 trading plan entered 08/21/2025.
• Timeliness: Filing dated 2026-02-12 for transactions on 2026-02-10 and 2026-02-11 appears timely (Form 4 is generally due within two business days).

Context

• The Feb 10 withholding (code F) indicates shares were surrendered/withheld to cover tax liabilities or exercise costs from prior equity awards or option exercises; the Feb 11 open-market sale looks like a separate disposition executed under a Rule 10b5-1 plan. Such withholdings and plan-based sales are common for insiders and do not necessarily signal a change in sentiment about the company.